Do you diagnose RSV based on signs and symptoms alone or do you utilize additional testing?
- How can you differentiate RSV infections from COVID-19 infections or other respiratory infections such as flu?

Related Content

Nursing home care | Image credit: Kzenon - stock.adobe.com

November 24th 2024

Low RSV Vaccination Rates in Nursing Homes Highlight Urgent Need for Uptake

Pearl Steinzor

Significant gaps in vaccination coverage among nursing home residents leaves vulnerable populations at risk for severe complications, report finds.

Air purifier | Image credit: Prathankarnpap - stock.adobe.com

November 22nd 2024

In-Room Air Purifiers Could Impact RSV Incidence Among Older Adults

Kennedy Ferruggia

Use of in-room air purifiers with HEPA-14 filters did not result in a significant reduction of acute respiratory infections.

RSV risk survey | Image credit: Richelle - stock.adobe.com

November 20th 2024

Community Pharmacies Hold Key Role in Protecting Older Adults From RSV

Pearl Steinzor

New research reveals gaps in respiratory syncytial virus (RSV) knowledge among older adults and emphasizes the impact community pharmacies can have at improving education and vaccine uptake.

Blood sample tube for RSV test. | Image credit: JUN LI - stock.adobe.com

November 15th 2024

RSV Vaccine Proven Effective in Reducing RSV-Related Hospitalizations

Kennedy Ferruggia

Respiratory syncytial virus (RSV) vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults, study finds.

RSV, COVID, Flu vaccines. | Image credit: angellodeco - stock.adobe.com

November 14th 2024

Impact of RSV on Hospitalizations in US Adults Prior to Vaccine Introduction

Pearl Steinzor

Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 years and older.

RSV vaccine vial with syringe - Respiratory syncytial virus shot | MargJohnsonVA - stock.adobe.com

October 23rd 2024

GSK's Arexvy Vaccine Shows Strong Efficacy Against RSV in Older Adults

Sophia Abene

The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus (RSV)-related lower respiratory tract disease in older adults over 3 seasons.

Related Content

November 24th 2024

Low RSV Vaccination Rates in Nursing Homes Highlight Urgent Need for Uptake

Pearl Steinzor

Significant gaps in vaccination coverage among nursing home residents leaves vulnerable populations at risk for severe complications, report finds.

November 22nd 2024

In-Room Air Purifiers Could Impact RSV Incidence Among Older Adults

Kennedy Ferruggia

Use of in-room air purifiers with HEPA-14 filters did not result in a significant reduction of acute respiratory infections.

November 20th 2024

Community Pharmacies Hold Key Role in Protecting Older Adults From RSV

Pearl Steinzor

New research reveals gaps in respiratory syncytial virus (RSV) knowledge among older adults and emphasizes the impact community pharmacies can have at improving education and vaccine uptake.

November 15th 2024

RSV Vaccine Proven Effective in Reducing RSV-Related Hospitalizations

Kennedy Ferruggia

Respiratory syncytial virus (RSV) vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults, study finds.

November 14th 2024

Impact of RSV on Hospitalizations in US Adults Prior to Vaccine Introduction

Pearl Steinzor

Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 years and older.

October 23rd 2024

GSK's Arexvy Vaccine Shows Strong Efficacy Against RSV in Older Adults

Sophia Abene

The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus (RSV)-related lower respiratory tract disease in older adults over 3 seasons.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions